Compare ELVN & KBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVN | KBR |
|---|---|---|
| Founded | 2016 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.4B |
| IPO Year | 2020 | 2006 |
| Metric | ELVN | KBR |
|---|---|---|
| Price | $49.14 | $37.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $74.42 | $44.14 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 1.74% |
| EPS Growth | 3.17 | ★ 15.05 |
| EPS | N/A | ★ 2.60 |
| Revenue | N/A | ★ $5,767,000,000.00 |
| Revenue This Year | N/A | $3.05 |
| Revenue Next Year | N/A | $5.30 |
| P/E Ratio | ★ N/A | $15.25 |
| Revenue Growth | N/A | ★ 2.27 |
| 52 Week Low | $14.79 | $29.94 |
| 52 Week High | $62.32 | $45.37 |
| Indicator | ELVN | KBR |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 45.97 |
| Support Level | $44.18 | $35.52 |
| Resistance Level | $52.39 | $37.80 |
| Average True Range (ATR) | 2.15 | 1.50 |
| MACD | 1.03 | -0.14 |
| Stochastic Oscillator | 92.95 | 13.84 |
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 36,000 people. The firm generated $7.8 billion in revenue in 2025.